Difference between revisions of "Talk:LR(0) ---- SLR(1) Parsers"
(Punk not dead <a href=" http://www.highhouseproductionpark.co.uk/contact-us ">topamax prescription over counter yt</a> "There's often someone who's noticed something that's not quite) |
(One moment, please <a href=" http://www.redplanetmusic.ch/accueil/ ">ordering diflucan ci</a> This stock has become li’l more than a tool for the insiders/institutions/funds who pretty much own) |
||
| Line 1: | Line 1: | ||
| − | + | One moment, please <a href=" http://www.redplanetmusic.ch/accueil/ ">ordering diflucan ci</a> This stock has become li’l more than a tool for the insiders/institutions/funds who pretty much own the float outright to shovel shares back and forth to bump the price in order to trap and loot short sellers. the numbers don’t add up. No one is applying affordability to the equation. The CEO guesstimates 15,000 afflicted with HoFH worldwide (more’n double the FDA estimate of one in a million). Based upon 2009 IRS statistics roughly one in two hundred Americans could (if they chose) afford a 300K prescription, course weâre more affluent than most in the world, USA GDP per capita is $49,800 (2012 est.), World GDP per capita is $12,400 (2012 est.), accordingly youâd have to assume a much smaller ratio able to afford it on a worldwide basis, assuming one in a thousand (probably still far too high) persons could afford the prescription (and choose it over less expensive treatments), youâd have a grand total of 15 customers and 4.5 million in annual revenue…don’t be fooled by short term results, it’s an accounting game, bottom line they’re still losing money…with a 2,500 million market cap created of BS and price fixing. | |
Revision as of 12:15, 5 September 2014
One moment, please <a href=" http://www.redplanetmusic.ch/accueil/ ">ordering diflucan ci</a> This stock has become li’l more than a tool for the insiders/institutions/funds who pretty much own the float outright to shovel shares back and forth to bump the price in order to trap and loot short sellers. the numbers don’t add up. No one is applying affordability to the equation. The CEO guesstimates 15,000 afflicted with HoFH worldwide (more’n double the FDA estimate of one in a million). Based upon 2009 IRS statistics roughly one in two hundred Americans could (if they chose) afford a 300K prescription, course weâre more affluent than most in the world, USA GDP per capita is $49,800 (2012 est.), World GDP per capita is $12,400 (2012 est.), accordingly youâd have to assume a much smaller ratio able to afford it on a worldwide basis, assuming one in a thousand (probably still far too high) persons could afford the prescription (and choose it over less expensive treatments), youâd have a grand total of 15 customers and 4.5 million in annual revenue…don’t be fooled by short term results, it’s an accounting game, bottom line they’re still losing money…with a 2,500 million market cap created of BS and price fixing.
